Agios Pharmaceuticals (AGIO) Given New $91.00 Price Target at Royal Bank of Canada

Agios Pharmaceuticals (NASDAQ:AGIO) had its price objective boosted by equities research analysts at Royal Bank of Canada to $91.00 in a note issued to investors on Thursday, The Fly reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s target price would suggest a potential upside of 30.20% from the stock’s current price. The analysts noted that the move was a valuation call.

Other analysts also recently issued research reports about the stock. Oppenheimer set a $83.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 26th. Zacks Investment Research raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $68.00 price target on the stock in a report on Tuesday, January 9th. BidaskClub raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, January 16th. ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Finally, SunTrust Banks set a $80.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, November 19th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $77.64.

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) traded up $1.74 during midday trading on Thursday, hitting $69.89. 4,065,596 shares of the company’s stock traded hands, compared to its average volume of 503,938. Agios Pharmaceuticals has a 12 month low of $39.24 and a 12 month high of $76.02. The stock has a market capitalization of $3,407.42, a P/E ratio of -11.15 and a beta of 1.83.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The company had revenue of $11.35 million for the quarter, compared to the consensus estimate of $10.85 million. During the same quarter in the prior year, the firm earned ($1.63) earnings per share. The company’s revenue for the quarter was up 26.4% compared to the same quarter last year. analysts predict that Agios Pharmaceuticals will post -6.59 earnings per share for the current year.

In other news, insider Scott Biller sold 2,146 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $62.69, for a total value of $134,532.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO David P. Schenkein sold 53,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $73.16, for a total transaction of $3,877,480.00. Following the completion of the transaction, the chief executive officer now directly owns 53,000 shares of the company’s stock, valued at approximately $3,877,480. The disclosure for this sale can be found here. In the last three months, insiders sold 80,130 shares of company stock valued at $5,561,250. Company insiders own 5.43% of the company’s stock.

Several large investors have recently bought and sold shares of AGIO. QS Investors LLC acquired a new position in shares of Agios Pharmaceuticals in the second quarter valued at approximately $144,000. State of Alaska Department of Revenue acquired a new position in Agios Pharmaceuticals during the fourth quarter worth approximately $160,000. Cubist Systematic Strategies LLC increased its position in Agios Pharmaceuticals by 1,041.0% during the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 3,123 shares during the last quarter. Bank of Montreal Can increased its position in Agios Pharmaceuticals by 74.8% during the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 1,520 shares during the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in Agios Pharmaceuticals during the third quarter worth approximately $225,000. 94.32% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Agios Pharmaceuticals (AGIO) Given New $91.00 Price Target at Royal Bank of Canada” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/01/21/agios-pharmaceuticals-agio-given-new-91-00-price-target-at-royal-bank-of-canada.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

The Fly

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)



Leave a Reply